CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
© 2024. The Author(s)..
One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipid (CoPoP) liposomes decorated with repaired and stabilized clade C HIV-1 Env trimers in a prefusion conformation. These particles exhibit high HIV-1 Env trimer decoration, serum stability and bind broadly neutralizing antibodies. Three sequential immunizations of female rabbits with CoPoP liposomes displaying a different clade C HIV-1 gp140 trimer at each dosing generate high HIV-1 Env-specific antibody responses. Additionally, serum neutralization is detectable against 18 of 20 multiclade tier 2 HIV-1 strains. Furthermore, the peak antibody titers induced by CoPoP liposomes can be recalled by subsequent heterologous immunization with Ad26-encoded membrane-bound stabilized Env antigens. Hence, a CoPoP liposome-based HIV-1 vaccine that can generate cross-clade neutralizing antibody immunity could potentially be a component of an efficacious HIV-1 vaccine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 11. Apr., Seite 3128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koornneef, Annemart [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AIDS Vaccines |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 25.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-47492-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370944119 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370944119 | ||
| 003 | DE-627 | ||
| 005 | 20240425233936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-47492-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370944119 | ||
| 035 | |a (NLM)38605096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koornneef, Annemart |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipid (CoPoP) liposomes decorated with repaired and stabilized clade C HIV-1 Env trimers in a prefusion conformation. These particles exhibit high HIV-1 Env trimer decoration, serum stability and bind broadly neutralizing antibodies. Three sequential immunizations of female rabbits with CoPoP liposomes displaying a different clade C HIV-1 gp140 trimer at each dosing generate high HIV-1 Env-specific antibody responses. Additionally, serum neutralization is detectable against 18 of 20 multiclade tier 2 HIV-1 strains. Furthermore, the peak antibody titers induced by CoPoP liposomes can be recalled by subsequent heterologous immunization with Ad26-encoded membrane-bound stabilized Env antigens. Hence, a CoPoP liposome-based HIV-1 vaccine that can generate cross-clade neutralizing antibody immunity could potentially be a component of an efficacious HIV-1 vaccine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Phospholipids |2 NLM | |
| 650 | 7 | |a HIV Antibodies |2 NLM | |
| 650 | 7 | |a env Gene Products, Human Immunodeficiency Virus |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a AIDS Vaccines |2 NLM | |
| 700 | 1 | |a Vanshylla, Kanika |e verfasserin |4 aut | |
| 700 | 1 | |a Hardenberg, Gijs |e verfasserin |4 aut | |
| 700 | 1 | |a Rutten, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Strokappe, Nika M |e verfasserin |4 aut | |
| 700 | 1 | |a Tolboom, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Vreugdenhil, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Boer, Karin Feddes-de |e verfasserin |4 aut | |
| 700 | 1 | |a Perkasa, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Blokland, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Burger, Judith A |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wei-Chiao |e verfasserin |4 aut | |
| 700 | 1 | |a Lovell, Jonathan F |e verfasserin |4 aut | |
| 700 | 1 | |a van Manen, Danielle |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Rogier W |e verfasserin |4 aut | |
| 700 | 1 | |a Zahn, Roland C |e verfasserin |4 aut | |
| 700 | 1 | |a Schuitemaker, Hanneke |e verfasserin |4 aut | |
| 700 | 1 | |a Langedijk, Johannes P M |e verfasserin |4 aut | |
| 700 | 1 | |a Wegmann, Frank |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 11. Apr., Seite 3128 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:11 |g month:04 |g pages:3128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-47492-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 11 |c 04 |h 3128 | ||